Q-omics provides the consensus-scored KCNJ18 profile across patient tissues and cancer cell-line models. KCNJ18 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KCNJ18 is differentially expressed in 8, with the highest sampling consensus in READ. Additionally, KCNJ18 RNA expression shows 6,573 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight HNSC, READ, and KIRC as cancer lineages where KCNJ18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNJ18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNJ18 survival associations across molecular data types. KCNJ18 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNJ18 RNA expression–survival associations across cancer types. High KCNJ18 expression shows unfavorable associations in LUAD, ACC, LUSC, UCEC and OV, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KCNJ18 RNA expression.
This table summarizes KCNJ18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in READ for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KCNJ18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNJ18 shows lower tumor expression in READ, PRAD and THCA and higher tumor expression in LUSC, LUAD and HNSC. The READ box plot shows higher KCNJ18 RNA expression in normal versus tumor tissue (log2 FC = −0.235, t-test p = .011).
This table shows molecular features associated with KCNJ18 in patient tissues and cancer cell lines. In patient samples, KCNJ18 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNJ18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma.
